BioCentury
ARTICLE | Clinical News

Inlyta axitinib regulatory update

May 28, 2012 7:00 AM UTC

EMA's CHMP issued a positive opinion recommending approval of Inlyta axitinib from Pfizer to treat advanced renal cell carcinoma after failure of prior treatment with Pfizer's Sutent sunitinib or a c...